Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Adenocarcinoma of Kidney”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableEnrolling By InvitationNCT00102544
What this trial is testing

Use of Tracking Devices to Locate Abnormalities During Invasive Procedures

Who this might be right for
AdenocarcinomaProstate NeoplasmsProstate Cancer+2 more
National Institutes of Health Clinical Center (CC) 3,894
Testing effectiveness (Phase 2)Study completedNCT00079612
What this trial is testing

Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer

Who this might be right for
Carcinoma, Renal Cell
Bayer 501
Large-scale testing (Phase 3)Study completedNCT00738530
What this trial is testing

Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Who this might be right for
Renal Cell Cancer
Hoffmann-La Roche 649
Not applicableStudy completedNCT01014065
What this trial is testing

A Prospective Study of Acute Cardiovascular Effects of First-line Sunitinib in Metastatic Renal Cell Carcinoma Patients (SUnitinib Prospective CardiovasculaR Effect)

Who this might be right for
Renal Cell CarcinomaCardiotoxicityHeart Failure+1 more
AHS Cancer Control Alberta 42
Large-scale testing (Phase 3)UnknownNCT00869011
What this trial is testing

Exercise for Patients With Renal Cell Cancer Receiving Sunitinib

Who this might be right for
Renal Cell Carcinoma
Charite University, Berlin, Germany 70
Not applicableStudy completedNCT05361434
What this trial is testing

The Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in Adults

Who this might be right for
Advanced Renal Cell Carcinoma
Ipsen 311
Not applicableUnknownNCT03259477
What this trial is testing

RFR Change of Precise Segmental Versus Complete Renal Arterial Clamping During LPN for Clinical T1 RCC

Who this might be right for
Renal Cell Carcinoma
Xuanwu Hospital, Beijing 100
Early research (Phase 1)Ended earlyNCT05861947
What this trial is testing

Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies

Who this might be right for
RelapseAdvanced Malignant NeoplasmNon Small Cell Lung Cancer+5 more
Aurigene Discovery Technologies Limited 21
Testing effectiveness (Phase 2)Ended earlyNCT00491738
What this trial is testing

A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R)

Who this might be right for
Renal Cell Carcinoma
Genentech, Inc. 16
Testing effectiveness (Phase 2)Study completedNCT02899078
What this trial is testing

Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer

Who this might be right for
Metastatic Renal Cell CancerStage IV Renal Cell Cancer
University of California, Davis 31
Early research (Phase 1)Active Not RecruitingNCT04696731
What this trial is testing

Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Who this might be right for
Advanced/Metastatic Clear Cell Renal Cell Carcinoma
Allogene Therapeutics 120
Not applicableStudy completedNCT01833728
What this trial is testing

A Comparison of Nefopam-propacetamol Combination and Propacetamol for Postoperative Quality of Recovery After Laparoscopic Nephrectomy

Who this might be right for
Renal Tumor
Yonsei University 16
Post-approval studies (Phase 4)Study completedNCT02596035
What this trial is testing

An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma

Who this might be right for
Renal Cell Carcinoma
Bristol-Myers Squibb 197
Testing effectiveness (Phase 2)Looking for participantsNCT06053658
What this trial is testing

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

Who this might be right for
Renal Cell Carcinoma
M.D. Anderson Cancer Center 48
Not applicableStudy completedNCT01649778
What this trial is testing

Observational Study of Real World Effectiveness Data and Safety in Patients Receiving Pazopanib With Advanced or Metastatic Renal Cell Carcinoma

Who this might be right for
Carcinoma, Renal Cell
Novartis Pharmaceuticals 662
Large-scale testing (Phase 3)Not Yet RecruitingNCT06959433
What this trial is testing

Lu-177 PSMA Treatment in Cell Renal Carcinoma

Who this might be right for
Metastatic Renal Cancer
Ankara University 20
Testing effectiveness (Phase 2)Ended earlyNCT00429026
What this trial is testing

Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation

Who this might be right for
Renal Cell Cancer
M.D. Anderson Cancer Center 40
Testing effectiveness (Phase 2)Study completedNCT00118326
What this trial is testing

Donor Bone Marrow Transplant in Treating Young Patients With Cancer or a Non-Cancerous Disease

Who this might be right for
Kidney CancerLeukemiaLymphoma+3 more
Fred Hutchinson Cancer Center
Testing effectiveness (Phase 2)Study completedNCT00113529
What this trial is testing

Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma

Who this might be right for
Carcinoma, Renal Cell
Pfizer 42
Testing effectiveness (Phase 2)Ended earlyNCT02089802
What this trial is testing

Optimizing Pazopanib Exposure in RCC Patients

Who this might be right for
Locally Advanced Renal Cell CarcinomaMetastatic Renal Cell Carcinoma
Interessenverband zur Qualitätssicherung der Arbeit niedergelassener Uro-Onkologen in Deutschland e. 6
Next Page